STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ACAD ACADIA PHARMACEUTICALS INCORPORATED StockScouter® Report

5

StockScouter® Score

ACADIA PHARMACEUTICALS INCORPORATED, a mid cap growth company in the healthcare sector, is expected to slightly outperform the market over the next six months with slightly less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The most recent quarterly earnings report was significantly higher than analysts’ consensus forecast. Positive
  • One or more less experienced analysts has modestly increased quarterly earnings estimates for ACAD. Positive/Neutral

 

Concerns

  • Earnings growth in the past year has decelerated moderately compared to earnings growth in the past three years. Negative
  • Short-term relative price momentum exhibits meaningful weakness. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that mid cap stocks will be neutral, growth stocks will be neutral, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 40% done.
Progress: 80% done.
Low
High

Core Model Grades

A
C
C
D

Previous Ratings

4
6
4